Literature DB >> 32126570

The relationship between hyperbilirubinemia and the promoter region and first exon of UGT1A1 gene polymorphisms in Vietnamese newborns.

Tien-Thanh Nguyen1,2, Wei Zhao1, Xi Yang1, Dan-Ni Zhong3.   

Abstract

BACKGROUND: To investigate the relationship between unexplained indirect hyperbilirubinemia of Vietnamese newborns and the polymorphism of the promoter TATA box and exon 1 of bilirubin uridine diphosphate glucuronosyltransferase (UGT1A1) gene.
METHODS: A total of 149 neonates were divided into the hyperbilirubinemia group (n = 99) and control group (n = 50). The gene polymorphisms of UGT1A1 gene in the two groups were detected by PCR and direct sequencing, which revealed the relationship between UGT1A1 polymorphism with neonatal hyperbilirubinemia of neonates. The types of UGT1A1 polymorphism in the hyperbilirubinemia group and the peak total serum bilirubin (PSB) levels with different genotypes were observed.
RESULTS: (1) (TA)7 insertion mutation, 211G>A, 189C>T, 190G>A, 378C>T and 686C>A were detected. (2) The allele frequency of 211G>A allele mutation was significantly different between the two groups (p < 0.05). (3) Logistic regression analysis showed that homozygosity and heterozygosity of 211G>A were both significantly associated with neonatal hyperbilirubinemia. (4) In the hyperbilirubinemia group, the peak total serum bilirubin level of 211G>A homozygous neonates was higher than that of the wild-type neonates (p < 0.05).
CONCLUSIONS: We noted that there was an association between neonates with unexplained indirect hyperbilirubinemia in Vietnam and the polymorphism of UGT1A1c.211G>A. In addition, the homozygous 211G>A polymorphism was related to the degree of hyperbilirubinemia. IMPACT: Our article provided data on UGT1A1 polymorphism distribution in the Vietnamese population, which have not been reported yet. Our findings revealed that mutations in UGT1A1 gene are risk factors for unexplained hyperbilirubinemia in Vietnamese neonates. Our article will strengthen the cognition of neonatal jaundice at the genetic level in the pediatric field in Vietnam.

Entities:  

Year:  2020        PMID: 32126570     DOI: 10.1038/s41390-020-0825-6

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  2 in total

1.  [Roles of UGT 1A1 gene mutation in the development of neonatal hyperbilirubinemia in Guangxi].

Authors:  Zong-yan Gao; Dan-ni Zhong; Yi Liu; You-nan Liu; Lu-ming Wei
Journal:  Zhonghua Er Ke Za Zhi       Date:  2010-09

2.  Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese.

Authors:  K Akaba; T Kimura; A Sasaki; S Tanabe; T Ikegami; M Hashimoto; H Umeda; H Yoshida; K Umetsu; H Chiba; I Yuasa; K Hayasaka
Journal:  Biochem Mol Biol Int       Date:  1998-09
  2 in total
  4 in total

1.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Alterations of Cytochrome P450s and UDP-Glucuronosyltransferases in Brain Under Diseases and Their Clinical Significances.

Authors:  Yun Sheng; Hanyu Yang; Tong Wu; Liang Zhu; Li Liu; Xiaodong Liu
Journal:  Front Pharmacol       Date:  2021-04-21       Impact factor: 5.810

3.  Effect of the genetic mutant G71R in uridine diphosphate-glucuronosyltransferase 1A1 on the conjugation of bilirubin.

Authors:  Hong Chen; Danni Zhong; Zongyan Gao; Xiaojing Wu
Journal:  Open Life Sci       Date:  2022-03-18       Impact factor: 0.938

4.  Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population.

Authors:  Chalirmporn Atasilp; Janjira Kanjanapipak; Jaratdao Vichayaprasertkul; Pimonpan Jinda; Rawiporn Tiyasirichokchai; Pornpen Srisawasdi; Chatchay Prempunpong; Monpat Chamnanphon; Apichaya Puangpetch; Natchaya Vanwong; Suwit Klongthalay; Thawinee Jantararoungtong; Chonlaphat Sukasem
Journal:  BMC Pediatr       Date:  2022-05-02       Impact factor: 2.567

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.